A recent filing with the Securities and Exchange Commission revealed that J. Robert Kerrey, a director at Tenet Healthcare Corp (NYSE:THC), has sold a significant number of shares in the company. The transactions, which took place on May 30 and 31, 2024, resulted in the sale of shares totaling over $1.9 million.
The SEC filing indicated that on May 30, Kerrey sold 6,358 shares at an average price of $133.20 and 7,964 shares at an average price of $134.65. These sales amounted to a total of $1,919,238, with prices ranging from $133.20 to $134.65 per share. Following these transactions, Kerrey's holdings in Tenet Healthcare decreased but still amounted to a substantial 46,403 shares.
Further sales occurred on May 31, where Kerrey sold 8,699 shares at an average price of $133.30, 697 shares at $134.44, and a final batch of 104 shares at $135.17. These transactions totaled $1,267,339, with the price per share ranging from $133.30 to $135.17. After these sales, it was reported that the director's directly owned shares dropped to zero, indicating that these shares were held indirectly by immediate family members.
The filing also noted gifts of securities to immediate family members, which were then sold. However, these gift transactions were reported with a transaction value of $0.
Investors often monitor insider transactions as they can provide insights into a company's health and the sentiment of its executives. The sale of shares by a director might be part of a personal financial strategy or could reflect their perspective on the company's future prospects.
Tenet Healthcare Corp, listed under the ticker symbol THC, is a multinational healthcare services company based in Dallas, Texas. It operates a network of hospitals and healthcare facilities across the United States.
For more detailed information regarding the transactions, the SEC filing includes a commitment by Kerrey to provide full information on the number of shares sold at each separate price upon request.
InvestingPro Insights
Amidst the recent insider selling activity at Tenet Healthcare Corp (NYSE:THC), current metrics and analyst revisions provide a broader perspective on the company's financial health and market position. Tenet Healthcare boasts a formidable Market Cap of $13.06B, reflecting its significant presence in the healthcare industry. The company's P/E Ratio stands at a competitive 5.16, suggesting that the stock could be undervalued relative to its earnings. Additionally, the Revenue Growth for the last twelve months as of Q1 2024 has been reported at 7.4%, indicating a solid upward trajectory in the company's earnings potential.
An InvestingPro Tip highlights that Tenet Healthcare has a perfect Piotroski Score of 9, which is a strong indicator of the company's financial stability. Furthermore, with 15 analysts having revised their earnings upwards for the upcoming period, there is an optimistic outlook on the company's future performance. This positive sentiment is supported by the fact that Tenet Healthcare's stock has yielded a strong return over the last year, with its price currently trading near its 52-week high.
For investors seeking a more comprehensive analysis and additional InvestingPro Tips, they can explore https://www.investing.com/pro/THC, where there are 11 more tips available. These insights could prove invaluable for those considering an investment in Tenet Healthcare. Moreover, readers can take advantage of the special offer using the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.